Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProShares Ultra Nasdaq Biotechnology (NQ:BIB)

69.53 -0.72 (-1.02%)
Official Closing Price Updated: 4:15 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ProShares Ultra Nasdaq Biotechnology

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally
Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday. 
Via Stocktwits
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn
President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon." 
Via Investor's Business Daily
Topics ETFs Economy Government
Friday Trades And June Summary
Trading performance has been very good year to date. I had thought I needed to tighten my belt but I made it by just fine. 
Via Talk Markets
Lifeline For 23andMe? Stock Jumps After Court Greenlights Bankruptcy Asset Sale, Retail Weighs Possible Rescue Deals
Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue... 
Via Stocktwits
Topics Bankruptcy
Tonix Pharma Dominates Retail Biotech Buzz After 1-for-100 Reverse Split, Sentiment Turns Neutral Amid Volatility
Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data. 
Via Stocktwits
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding
Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 
Via Stocktwits
Amgen, Inc. Dividend Stock Analysis
Amgen Inc. is one of the world's leading biotech companies with major treatments for anemia, neutropenia, rheumatoid and psoriatic arthritis, psoriasis, cancer and osteoporosis. 
Via Talk Markets
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
The 7 Best ETFs to Buy to Cover 2023’s Biggest Investing Opportunities
These are some of the best ETFs to buy heading into New Year 2023. Not only do they offer solid diversification, but they're cheap. 
Via InvestorPlace
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
Market Briefing For Tuesday, July 5, 2022
This is a complicated time. Everything is bifurcated. Stocks. The political backdrop. Society itself. 
Via Talk Markets
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: 
Via Benzinga
Take A Look At The Top-Performing Biotech ETFs YTD
The biotechnology sector has been grabbing the headlines on the new coronavirus vaccine and drug-related updates. The space has also kept its promise of generating returns, with the Nasdaq... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.